Get started
Author

Tristen S. Park

Treating cancer with genetically engineered T cells
2011 · Tristen S. Park, Steven A. Rosenberg, et al. · Trends in biotechnology · 218
MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases
2016 · Sid P. Kerkar, Zeng-Feng Wang, et al. · Journal of Immunotherapy · 74
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
2021 · Julia Foldi, Andrea Silber, et al. · npj Breast Cancer · 71
PDF
Association of Medicaid Expansion Under the Affordable Care Act With Breast Cancer Stage at Diagnosis
2020 · Justin M. Le Blanc, Danielle R. Heller, et al. · JAMA Surgery · 71
PDF
Immunotherapy Treatment for Triple Negative Breast Cancer
2021 · Elizabeth R. Berger, Tristen Park, et al. · Pharmaceuticals · 68
PDF
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
2020 · Kelly Olino, Tristen Park, et al. · Seminars in Cancer Biology · 66
Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers
2015 · Tristen S. Park, Eric M. Groh, et al. · Journal of Immunotherapy · 53
The impact of communication style on patient satisfaction
2019 · Amelia A. Trant, Borbala Szekely, et al. · Breast Cancer Research and Treatment · 35
Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients
2017 · Tristen S. Park, Giao Q. Phan, et al. · Annals of Surgical Oncology · 35
PDF
Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer
2021 · Angeleke Saridakis, Elizabeth R. Berger, et al. · Annals of Surgical Oncology · 33
The Association of Extent of Axillary Surgery and Survival in Women with N2–3 Invasive Breast Cancer
2018 · Tristen S. Park, Samantha M. Thomas, et al. · Annals of Surgical Oncology · 31
Characteristics and Long-Term Risk of Breast Angiosarcoma
2021 · Ann-Kristin U. Friedrich, Emily S. Reisenbichler, et al. · Annals of Surgical Oncology · 30
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC
2022 · Julia Foldi, Adriana Kahn, et al. · Clinical Cancer Research · 21
PDF
Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy
2021 · Julia Foldi, Mariya Rozenblit, et al. · Current Treatment Options in Oncology · 21
Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011
2017 · Cecilia T. Ong, Samantha M. Thomas, et al. · Annals of Surgical Oncology · 21
Gamma-Retroviral Vector Design for the Co-Expression of Artificial microRNAs and Therapeutic Proteins
2014 · Tristen S. Park, Daniel Abate-Daga, et al. · Nucleic Acid Therapeutics · 10
Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest
2023 · Leah Kim, Magdalena Coman, et al. · Annals of Surgical Oncology · 9
National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer
2024 · Leah S. Kim, Miranda S. Moore, et al. · Annals of Surgical Oncology · 8
Association of Medicaid Expansion with Post-mastectomy Reconstruction Rates
2022 · Justin Le Blanc, Mehra Golshan, et al. · Annals of Surgical Oncology · 8
Use of the piggyBac Transposon to Create Stable Packaging Cell Lines for the Production of Clinical-Grade Self-Inactivating γ-Retroviral Vectors
2014 · Steven A. Feldman, Hui Xu, et al. · Human Gene Therapy Methods · 8
Core Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast Cancer
2023 · Magdalena M. Coman, Lajos Pusztai, et al. · Journal of Immunotherapy · 5
Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
2022 · Julia Foldi, Andrea Silber, et al. · npj Breast Cancer · 4
PDF
Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer
2025 · Ismail Ajjawi, Alejandro Rios, et al. · Breast Cancer Research and Treatment · 3
Clinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer
2025 · Ismail Ajjawi, Alejandro Rios, et al. · Cancers · 2
PDF
Abstract P3-09-05: Predictive markers of response to durvalumab concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple negative breast cancer (TNBC)
2020 · Kim RM Blenman, Xiaotong Li, et al. · Cancer Research · 2
Works count: 64
Citation count: 913
H-index: 15
I10-index: 16
Year
Topic
Type